Pharmacological inhibition of TLR3 with the small molecule C4a, did not only suppress the pro-inflammatory and pro-osteogenic effects in human VICs and VECs in vitro, but also suppressed AS development in vivo. The gene discussed is TLR3; the disease is aortic valve stenosis.